Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
OBJECTIVE
The aim of this study was to investigate the market uptake of biologic and small-molecule-targeted oncology drugs in Europe.


METHODS
Targeted oncology drugs that were used in one of the selected European countries before the end of 2007 were eligible for inclusion in the analysis. The following European countries were included: Austria, Croatia, France, Germany, Hungary, Italy, Slovenia, and the United Kingdom. Monetary market uptake of targeted oncology drugs was assessed by using sales data (in euros) obtained from 2 large data- bases for the period 1997-2007. Market uptake was assessed in terms of expenditures for specific drugs in euros per capita and in market shares.


RESULTS
The monetary market uptake of targeted oncology drugs had an exponential growth from 1997 to 2007 in all comparison countries and reached 40% of the total oncology drug market in 2007. Although the various European countries allocate substantially different amounts of resources per capita for oncology drugs, the share of expenditures attributed to targeted oncology drugs did not differ substantially among the countries. Biologic molecules were used in clinical practice before the small-molecule-targeted oncology drugs. Targeted oncology drugs that were introduced first to clinical practice in most of the comparison countries (ie, rituximab, trastuzumab, imatinib mesylate) maintained the leading positions on the market throughout the period of the analysis. In 2007, approximately 25% of all expenditures for oncology drugs were attributed to biologic oncology drugs, and approximately 15% were spent on small-molecule-targeted oncology drugs.


CONCLUSIONS
Expenditures on targeted oncology drugs have been increasing exponentially in Europe throughout the past decade and have reached a 40% share of the oncology drug market. As of 2007, the market share of biologic oncology drugs was higher than the market share of small-molecule-targeted oncology drugs.
Obradovic
Marko
M
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Mrhar
Ales
A
Kos
Mitja
M
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001688:Biological Products / Q000191:economics / Q000627:therapeutic use*; D003132:Commerce / Q000191:economics*; D019992:Databases as Topic; D017277:Drug Approval; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D004363:Drug Utilization / Q000191:economics; D005060:Europe; D005102:Health Expenditures; D006801:Humans; D013997:Time Factors
D000970:Antineoplastic Agents; D001688:Biological Products